Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.56 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3383408 | 1.00 | CHRM1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL5519522 | 1.00 | CHRM1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL25944554 | 0.86 | CA2 (0.52) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL25944552 | 0.86 | CA2 (0.52) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL29030273 | 0.86 | CA2 (0.52) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL11748330 | 0.85 | GRIK1 (0.53) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL576209 | 0.83 | GRIK1 (0.60) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL7082795 | 0.82 | GRIK1 (0.46) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL7085892 | 0.82 | GRIK1 (0.46) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL7545224 | 0.77 | GRIK1 (0.54) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114828841-A | Use of valproic acid for reducing post-operative scarring after glaucoma surgery | 参天制药株式会社 | 2022-07-29 | — | — | CN | claimed |
| WO-2021118469-A1 | USE OF VALPROIC ACID FOR REDUCING POST-OPERATIVE SCARRING FOLLOWING A GLAUCOMA SURGERY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | WO | claimed |
| US-20020156320-A1 | Enantioselective synthesis of valproic acid analogues | NAU HEINZ (DE) | 2002-10-24 | — | — | US | claimed |
| US-6458840-B2 | 2-N-PROPYL-4-HEXYNOIC ACID; REDUCED ADVERSE EFFECTS INCLUDING NEUROTOXICITY AND TERATOGENIC POTENTIAL COMPARED TO VALPROIC ACID | AMERICAN BIOGENETIC SCIENCES, INC. | 2002-10-01 | — | — | US | claimed |
| US-20010031789-A1 | Use of valproic acid analog for the treatment and prevention of migraine and affective illness | AMERICAN BIOGENETIC SCIENCES, INC. | 2001-10-18 | — | — | US | claimed |
| US-6268396-B1 | ADMINISTERING 2-N-PROPYL-4-HEXYNOIC ACID | AMERICAN BIOGENETIC SCIENCES, INC. | 2001-07-31 | — | — | US | claimed |
| EP-1089725-A1 | THE USE OF VALPROIC ACID ANALOG FOR THE TREATMENT AND PREVENTION OF MIGRAINE AND AFFECTIVE ILLNESS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 2001-04-11 | — | — | EP | claimed |
| WO-1999066920-A1 | THE USE OF VALPROIC ACID ANALOG FOR THE TREATMENT AND PREVENTION OF MIGRAINE AND AFFECTIVE ILLNESS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1999-12-29 | — | — | WO | claimed |
| US-5786380-A | MODIFIED VALPROIC ACID | NAU, HEINZ (DE) | 1998-07-28 | — | — | US | claimed |
| US-20230015595-A1 | USE OF VALPROIC ACID FOR REDUCING POST-OPERATIVE SCARRING FOLLOWING A GLAUCOMA SURGERY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| CN-114828841-A | Use of valproic acid for reducing post-operative scarring after glaucoma surgery | 参天制药株式会社 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021118469-A1 | USE OF VALPROIC ACID FOR REDUCING POST-OPERATIVE SCARRING FOLLOWING A GLAUCOMA SURGERY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | WO | disclosed |
| US-10640481-B2 | Methods for producing Beraprost and its derivatives | LUNG BIOTECHNOLOGY PBC (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190202797-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | LUNG BIOTECHNOLOGY PBC (US) | 2019-07-04 | — | — | US | disclosed |
| EP-1089725-A1 | THE USE OF VALPROIC ACID ANALOG FOR THE TREATMENT AND PREVENTION OF MIGRAINE AND AFFECTIVE ILLNESS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999066920-A1 | THE USE OF VALPROIC ACID ANALOG FOR THE TREATMENT AND PREVENTION OF MIGRAINE AND AFFECTIVE ILLNESS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999066920-A1 | THE USE OF VALPROIC ACID ANALOG FOR THE TREATMENT AND PREVENTION OF MIGRAINE AND AFFECTIVE ILLNESS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5786380-A | MODIFIED VALPROIC ACID | NAU, HEINZ (DE) | 1998-07-28 | — | — | US | disclosed |
| EP-0778820-A1 | NEUROTROPHIC AND ANTIPROLIFERATIVE COMPOUNDS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1997-06-18 | — | — | EP | disclosed |
| WO-1996006821-A1 | NEUROTROPHIC AND ANTIPROLIFERATIVE COMPOUNDS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156320-A1 | Enantioselective synthesis of valproic acid analogues | COASY, ACADM, CYP2A6 | CHRM1 3665/4885AKR1A1 297/4885CHRM3 3189/4885 |
| US-10640481-B2 | Methods for producing Beraprost and its derivatives | UMPS, GGPS1, DHPS | CHRM1 4844/4885AKR1A1 986/4885CHRM3 4235/4885 |
| US-20190202797-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | UMPS, GGPS1, DHPS | CHRM1 4844/4885AKR1A1 986/4885CHRM3 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.